Robert Malenka Sells 6,622 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,622 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $18.12, for a total transaction of $119,990.64. Following the completion of the transaction, the director directly owned 351,611 shares of the company’s stock, valued at $6,371,191.32. This represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Maplight Therapeutics Price Performance

Shares of Maplight Therapeutics stock opened at $17.22 on Friday. The stock has a market capitalization of $781.32 million and a P/E ratio of -0.46. The firm has a 50-day simple moving average of $18.15. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Ratings Changes

MPLT has been the subject of a number of research reports. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective for the company. Stifel Nicolaus assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 target price on the stock. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Jefferies Financial Group assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Hedge Funds Weigh In On Maplight Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in shares of Maplight Therapeutics during the fourth quarter worth approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics in the fourth quarter worth approximately $70,000. New York State Common Retirement Fund purchased a new position in Maplight Therapeutics during the 4th quarter worth $93,000. MetLife Investment Management LLC bought a new stake in Maplight Therapeutics during the 4th quarter valued at $172,000. Finally, Walleye Capital LLC purchased a new stake in shares of Maplight Therapeutics in the 4th quarter worth $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.